induction-of-mouse-lung-injury-by-endotracheal-injection-of-bleomycin

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Pulmonary fibrosis is a hallmark of several human lung diseases with a different etiology. Since current therapies are rather limited, mouse models ...

Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII

Producing advanced therapy medicinal products (ATMP) according to Good Manufacturing Practice (GMP) guidelines represents a global challenge for the expansion of cells intended for human use. Mesenchymal stromal cells (MSCs) from different sources are one of the most actively developed cell type for a variety of clinical applications in cellular therapy. Complying with GMP means defining accurately both the production process and the release criteria required for a final safe product. We have here reported our manufacturing experience on 103 consecutive clinical-grade in vitro expansions of both bone marrow-derived and umbilical cord-derived mesenchymal stromal cells together with description of methods and reagents utilized in our Cell Factory. The same animal- and serum-free medium, additioned with human platelet lysate, has been used for all the expansions performed. This is the largest experience published so far with this alternative and clinical-grade reagent (compared to the traditional fetal bovine serum) and shows the feasibility and the reproducibility of the method. Indeed, we have been able to produce a sufficient number of MSCs to treat 57 patients so far, enrolled in 7 different experimental phase I/II protocols. 

Clinical grade expansion of MSCs.

We analyzed the results of routine sterility testing performed in our center over the last 10 years, in the context both hematopoietic stem cell transplantation (HSCT) and Advanced Therapeutic Medicinal Products (ATMPs).

Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance.

Mesenchymal stromal cell (MSC)-based therapy is a promising strategy for preventing the progression of chronic kidney disease (CKD), with the potential to induce tissue regeneration. In search of the best cellular source we compared, in the rat model of adriamycin (ADR) nephropathy, the regenerative potential of human stromal cells of non-renal origin, such as bone marrow (bm) MSCs and umbilical cord (uc) MSCs, with that of newly discovered stromal cells of renal origin, the kidney perivascular cells (kPSCs) known to exhibit tissue-specific properties.

Chiara Capelli

UOS Centro di Terapia Cellulare "G. Lanzani"

Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

Chiara Capelli

.css-o250i3{font-size:18px;font-family:Open Sans,sans-serif;line-height:21.6px;}UOS Centro di Terapia Cellulare "G. Lanzani"

Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII

Induction of Mouse Lung Injury by Endotracheal Injection of Bleomycin

UOS Centro di Terapia Cellulare "G. Lanzani"